📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-19 18:03
570 analysed today
570
Today
133,459
All-time analysed
40,112
Positive
6,281
Negative
79,251
Neutral
7,747
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
19 announcements match the current filters (relevance ≥ 5).
Gaudium IVF Q1 FY27 Call: Targets 30% FY27 Revenue Growth, 10 New Hubs Planned
Gaudium IVF reported Q1 FY27 revenue growth of 9.1% YoY to ₹19.4 crore, with EBITDA of ₹2.4 crore and PAT of ₹1.8 crore, reflecting pre-investments for expansion. Management reiterated FY27 revenue growth guidance of 30% YoY. The company is executing its 19-centre IPO rollout plan, aiming for 10 new hubs in FY27 (South Extension operational, Gurgaon and Nagpur opening shortly) alongside international spokes in Paris, Nigeria, and Sydney.
Confidence: HIGH
What changedSubmission of the formal transcript for the Q1 FY27 earnings conference call held on August 14, 2026.
Why it mattersProvides detailed management commentary on the 30% FY27 growth target, margin trajectory, AI clinical tool integration, and network expansion status across India and international spokes.
Q1 FY27 Revenue: ₹19.4 croreQ1 FY27 EBITDA: ₹2.4 croreQ1 FY27 PAT: ₹1.8 croreFY27 Revenue Growth Guidance: 30%FY27 Planned New Hubs: 10 hubs
📅 Short termFocus will remain on the execution and footfall traction of recently launched hubs (South Delhi, Gurgaon, Nagpur).
📈 Long termStructural tailwinds from the ART & Surrogacy Act consolidation, combined with proprietary AI signature labs and Tier-2 hub-and-spoke expansion, support multi-year volume growth.
⚠ Risk flags
- Execution delays in opening new hubs
- Near-term margin drag from upfront hub setup costs prior to breakeven
Key Highlights
Q1 FY27 revenue increased 9.1% YoY to ₹19.4 crore, with EBITDA at ₹2.4 crore and PAT at ₹1.8 crore
Management guided for 30% YoY revenue growth in FY27 with sustained EBITDA and PAT margins
Targeting 10 new hubs in FY27 out of 19 planned IPO rollout centres; Gurgaon and Nagpur launching in August/September 2026
Reported first-attempt pregnancy success rate at 62% and cumulative rate at 85%, supported by AI embryology tools SiD and ERICA
👀 What to Watch
Track operational launch timelines and ramp-up metrics of upcoming hubs in Gurgaon and Nagpur, and monitor margin expansion in subsequent quarters as new hubs mature.
Gaudium IVF Revises Q1 FY27 Presentation; Discloses Rs 2.53 Cr One-Time Marketing Cost
Gaudium IVF issued a revised Q1 FY27 investor presentation to correct EBITDA figures and disclose a one-time marketing expense of Rs 2.53 crore related to its AI tools, SID and ERICA. The consolidated adjusted EBITDA is now reported at Rs 5.33 crore with a 27.49% margin, while standalone adjusted EBITDA stands at Rs 5.08 crore (37.12% margin). The company reported Q1 FY27 revenue of Rs 19.38 crore, a decline from the Rs 24.51 crore reported in Dec 2025. Management highlighted an aggressive expansion plan to add 10 new hubs by FY29, starting with two in FY27.
Confidence: HIGH
What changedThe company corrected its previously filed investor presentation to include a specific one-time marketing expense and revised its Adjusted EBITDA margin calculations.
Why it mattersThe disclosure clarifies that the margin pressure in Q1 FY27 was largely due to a non-recurring marketing investment (representing ~13% of quarterly revenue), providing a clearer picture of underlying operational profitability.
One-time marketing cost: Rs 253.24 lakhsMarketing cost vs Q1 Revenue: ~13.07%Consolidated Adjusted EBITDA Margin: 27.49%Average Revenue Per Patient: Rs 3.5 lakhsPlanned Hub Expansion (FY27-FY29): 11 units
📅 Short termThe clarification of one-time costs may support sentiment as it explains the sequential dip in profitability from the Dec 2025 quarter.
📈 Long termThe company is positioning itself as an AI-driven IVF platform with a plan to more than double its hub count (from 8 to 19) by FY29, targeting a highly underpenetrated market.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High marketing-to-revenue ratio
- Execution risk associated with rapid hub expansion
- Revenue concentration in IVF treatments (66%)
Key Highlights
One-time marketing cost of Rs 253.24 lakhs incurred for AI tools SID and ERICA in Q1 FY27
Consolidated Adjusted EBITDA corrected to Rs 532.75 lakhs, representing a 27.49% margin
Average Revenue Per Patient (ARPP) reported at Rs 3.5 lakhs with a 62% first-attempt success rate
Expansion roadmap includes 2 new hubs in FY27 (Delhi/NCR and Nagpur) and 8 hubs in FY28
Revenue mix dominated by IVF treatments at 66.24%, followed by Pharmacy at 29.41%
👀 What to Watch
Investors should monitor the execution of the 10-hub expansion plan and whether the one-time marketing spend of Rs 2.53 crore translates into higher patient footfalls in subsequent quarters.
Gaudium IVF Q1 FY27: Rs 19.38 Cr Revenue; Expansion Costs Impact Margins
Gaudium IVF reported Q1 FY27 revenue of Rs 19.38 cr, showing a moderation compared to the Dec 2025 quarter (Rs 24.51 cr) due to expansion-related costs. The company currently operates 8 hubs and 28 spokes across 9 states, with an average revenue per patient of Rs 3.5 lakhs. Profitability was impacted by investments in new hubs in Gurgaon and Nagpur and AI-led embryology tools, resulting in an adjusted EBITDA margin of 27.49%. Despite short-term margin pressure, the company maintains a high first-attempt success rate of 62%.
Confidence: HIGH
What changedThe company has transitioned from a private entity to a listed player, now disclosing detailed operational metrics including ARPP and AI-driven success rate improvements.
Why it mattersThe IVF industry in India is highly underpenetrated (<2%), and Gaudium is positioning itself as an organized, AI-enabled platform to capture the projected 13.1% industry CAGR.
Q1 FY27 Revenue: Rs 19.38 crAdjusted EBITDA Margin: 27.49%Average Revenue Per Patient: Rs 3.5 lakhsMarket Capitalisation: Rs 822.13 crPromoter Holding: 71%
📅 Short termThe stock may see some pressure or sideways movement as the market digests the sequential revenue decline and the impact of expansion costs on current margins.
📈 Long termThe long-term outlook remains tied to the company's ability to scale its hub-and-spoke model and maintain clinical success rates above the industry average in a growing market.
⚠ Risk flags
- Expansion-related cost overruns
- High concentration of revenue from IVF treatments
- Regulatory risks associated with the ART (Regulation) Act
Key Highlights
Network consists of 8 Hubs and 28 Spokes across 9 Indian states as of August 2026.
Average Revenue Per Patient (ARPP) is reported at Rs 3.5 lakhs.
IVF treatment accounts for 66.24% of revenue, while Pharmacy contributes 29.41%.
Adjusted EBITDA stood at Rs 5.33 cr with a margin of 27.49% for the period.
India IVF market is projected to grow at a 13.1% CAGR to reach $4.54 billion by 2034.
👀 What to Watch
Investors should monitor the execution timeline and ramp-up of the under-construction centers in Gurgaon and Nagpur to see if they offset current expansion costs. Additionally, watch for improvements in success rates and patient conversion following the integration of AI tools SiD and ERICA.
9.1% Revenue Growth in Q1FY27; EBITDA Drops 53% on Expansion Costs; ₹15 Cr Lucknow Project Approved
Gaudium IVF reported Q1 FY27 revenue of ₹19.4 Cr, a 9.1% YoY increase, though profitability was significantly impacted by expansion activities. EBITDA fell 53% YoY to ₹2.4 Cr as margins compressed from 29% to 12.5% due to pre-operational costs for new hubs and clinical hiring. The company is executing a 19-centre expansion roadmap, with the South Extension hub already operational and a new ₹15 Cr hospital approved in Lucknow. Management indicates that excluding one-off expansion costs, EBITDA margins would have remained steady at approximately 27.6%.
Confidence: HIGH
What changedThe company has transitioned into an aggressive expansion phase, sacrificing short-term margins (down 1651 bps) to fund a 19-centre rollout and entry into the Uttar Pradesh market.
Why it mattersThe IVF market is highly fragmented; Gaudium's ability to scale from 8 hubs to 27 hubs while maintaining its 62% success rate will determine its long-term valuation and market leadership.
Q1 FY27 Revenue: ₹19.4 CrEBITDA Margin: 12.51%Lucknow Project Cost: ₹15 CrYoY PAT Growth: -42.27%Planned Hubs FY27: 10
📅 Short termThe stock may face pressure due to the sharp decline in EBITDA and PAT, as the market digests the high cost of expansion versus the modest 9% revenue growth.
📈 Long termIf the company successfully executes its 19-centre expansion and restores margins to the 27% level seen in mature hubs, it could represent significant structural growth.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Margin compression from front-loaded expansion costs
- Execution risk in rolling out 10 hubs within a single financial year
- High clinical talent acquisition costs
Key Highlights
Revenue from operations grew 9.13% YoY to ₹19.38 Cr in Q1 FY27.
EBITDA declined 52.96% YoY to ₹2.42 Cr due to front-loaded costs for the FY27 hub rollout.
Board approved a new ₹15 Cr hospital in Lucknow, Uttar Pradesh, under a 30-year lease.
Network currently stands at 8 hubs and 28 spokes with a 62% first-attempt pregnancy success rate.
Expansion plan includes 10 hubs in FY27, 8 in FY28, and 1 in FY29 to reach a total of 19 new centres.
👀 What to Watch
Monitor the revenue ramp-up and margin recovery in the upcoming quarters as the 10 planned hubs for FY27 become operational and move toward steady-state utilization.
Gaudium IVF Approves Q1 FY27 Results; Appoints Secretarial Auditor for 5-Year Term
Gaudium IVF and Women Health Limited approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, during its board meeting on August 13, 2026. The company re-appointed Ram Rattan & Associates as Internal Auditor for FY 2026-27 and proposed Suresh Nainwal & Company as Secretarial Auditor for a five-year term. Additionally, the board reviewed the statement of deviation or variation under Regulation 32 regarding the utilization of fundraise proceeds. These actions represent standard quarterly compliance and governance updates.
Confidence: HIGH
What changedThe company has finalized its financial reporting for the first quarter of FY27 and updated its audit oversight team.
Why it mattersRegular financial reporting and the appointment of long-term auditors are essential for maintaining corporate governance and transparency for a listed entity.
Quarter ended: June 30, 2026Secretarial Auditor Term: 5 consecutive yearsInternal Auditor Tenure: FY 2026-27Board Meeting Date: August 13, 2026
📅 Short termThe stock may react to the specific earnings figures contained in the Q1 results over the coming days.
📈 Long termLimited; these are routine administrative and financial reporting activities that support long-term governance.
Key Highlights
Approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026
Re-appointed Ram Rattan & Associates as Internal Auditor for the Financial Year 2026-27
Proposed appointment of Suresh Nainwal & Company as Secretarial Auditor for a 5-year term (FY 2026-27 to FY 2030-31)
Reviewed the Statement of Deviation(s) or Variation(s) for fund utilization as per Regulation 32
👀 What to Watch
Investors should review the detailed Q1 FY27 financial statements to assess revenue growth and margin trends. Monitor the upcoming Annual General Meeting for the formal approval of the new secretarial auditor.
Gaudium IVF Reports ₹1.66 Cr Q1 PAT; Reallocates ₹1.93 Cr IPO Surplus to Corporate Purposes
Gaudium IVF and Women Health Limited reported a standalone revenue of ₹13.68 cr for Q1 FY27, a significant sequential decline from ₹22.17 cr in Q4 FY26. The company has successfully utilized ₹18.07 cr of its IPO proceeds to become debt-free as of June 30, 2026. Capital expenditure for new IVF centers is in the early stages, with only ₹1.03 cr spent out of the ₹50 cr allocated. Additionally, the board approved the appointment of M/s. Suresh Nainwal & Company as Secretarial Auditors for a five-year term.
Confidence: HIGH
What changedThe company reported its first full quarter results post-listing, confirmed its debt-free status, and appointed new secretarial auditors for a 5-year term.
Why it mattersWhile the company is now debt-free, the sharp sequential drop in revenue and profit suggests volatility in quarterly performance; the slow start to capex deployment is a key factor for long-term growth tracking.
Q1 FY27 Revenue: ₹13.68 crQ1 FY27 PAT: ₹1.66 crIPO Fresh Issue Proceeds: ₹90.00 crDebt Repayment Utilized: ₹18.07 crNew IVF Center Capex (Allocated): ₹50.00 crNew IVF Center Capex (Spent): ₹1.03 cr
📅 Short termThe market may react to the sequential decline in profitability and revenue compared to the March 2026 quarter.
📈 Long termLong-term value creation depends on the successful rollout of new IVF centers using the remaining ₹48.97 cr of allocated IPO funds.
⚠ Risk flags
- Significant sequential decline in net profit
- Slow utilization of expansion capital
Key Highlights
Q1 FY27 standalone revenue stood at ₹13.68 cr, down 38% from ₹22.17 cr in the previous quarter.
Net profit for the quarter was ₹1.66 cr, compared to ₹7.73 cr in the preceding quarter ended March 2026.
Utilized ₹18.07 cr to fully repay outstanding borrowings, achieving a debt-free status for the earmarked IPO objects.
Only ₹1.03 cr (approx. 2%) of the ₹50 cr IPO allocation for new IVF centers has been deployed as of June 30, 2026.
Reallocated ₹1.93 cr surplus from the debt repayment fund to General Corporate Purposes (GCP).
👀 What to Watch
Investors should monitor the pace of the ₹50 cr capex deployment for new IVF centers, as the current utilization is minimal and future growth depends on this expansion.
₹13.68 Cr Q1 Revenue: Gaudium IVF Reports 11.5% YoY Growth, Reallocates IPO Funds
Gaudium IVF reported standalone revenue of ₹13.68 cr for Q1 FY27, representing an 11.5% YoY growth but a sharp 38% sequential decline from Q4 FY26. Net profit for the quarter stood at ₹1.66 cr, down significantly from ₹7.73 cr in the preceding quarter. The company has utilized only ₹1.03 cr of its ₹50 cr IPO capex budget for new IVF centers as of June 2026. Additionally, the board approved reallocating ₹1.93 cr of unspent debt repayment funds toward general corporate purposes after clearing all outstanding borrowings of ₹18.07 cr.
Confidence: HIGH
What changedThe company released its first-quarter results post-IPO, appointed a new secretarial auditor for a five-year term, and reallocated surplus IPO funds from debt repayment to general corporate use.
Why it mattersWhile the company is now debt-free regarding its IPO-targeted borrowings, the sharp sequential decline in profitability and slow capex rollout are key performance indicators to watch in the medical facilities sector.
Q1 FY27 Revenue: ₹13.68 crQ1 FY27 PAT: ₹1.66 crIPO Capex Allocation: ₹50.00 crCapex vs FY26 Revenue: ~70%Debt Repaid from IPO: ₹18.07 cr
📅 Short termThe stock may face pressure due to the 78% QoQ decline in net profit and the slow start to the expansion projects funded by the IPO.
📈 Long termLong-term value depends on the successful establishment of new IVF centers using the remaining ₹48.97 cr capex budget, which represents a significant capacity increase relative to current operations.
⚠ Risk flags
- Slow utilization of IPO proceeds for core expansion
- Significant sequential margin contraction
- High dependence on new center execution for growth
Key Highlights
Q1 FY27 revenue reached ₹13.68 cr, up 11.5% compared to ₹12.27 cr in Q1 FY26.
Net profit dropped to ₹1.66 cr from ₹7.73 cr in the previous quarter (Q4 FY26).
Only ₹1.03 cr (approx. 2%) of the ₹50 cr IPO allocation for new IVF centers has been utilized.
Successfully repaid ₹18.07 cr in debt using IPO proceeds, making the company debt-free on those specific facilities.
Appointed M/s. Suresh Nainwal & Company as Secretarial Auditor for a 5-year term (FY27-FY31).
👀 What to Watch
Investors should monitor the execution timeline of the ₹50 cr expansion plan, as the slow initial deployment of IPO funds for new centers may delay projected revenue growth.
Gaudium IVF Q1 PAT at ₹1.66 Cr; IPO Debt Repayment of ₹18.07 Cr Completed
Gaudium IVF reported a standalone revenue of ₹13.67 cr for Q1 FY27, a sequential decline from ₹22.16 cr in Q4 FY26. Net profit fell to ₹1.66 cr compared to ₹7.73 cr in the previous quarter, primarily due to higher 'other expenses' and lower operational income. A key positive is the utilization of ₹18.07 cr from IPO proceeds to clear all outstanding debt, making the company debt-free. However, execution on the planned ₹50 cr expansion for new IVF centers is slow, with only ₹1.03 cr deployed so far.
Confidence: HIGH
What changedThe company has utilized IPO proceeds to clear its entire debt of ₹18.07 cr and reallocated a minor surplus of ₹1.92 cr to general corporate purposes.
Why it mattersWhile the company is now debt-free, the significant sequential drop in revenue and profit suggests operational volatility or seasonality that needs to be assessed against the long-term expansion plan.
Q1 Revenue (Standalone): ₹13.67 crQ1 PAT (Standalone): ₹1.66 crDebt Repaid from IPO: ₹18.07 crNew IVF Center Capex Budget: ₹50.00 crCapex Utilized to Date: ₹1.03 crFinance Costs (QoQ Change): Down from ₹1.23 cr to ₹0.32 cr
📅 Short termThe market may react cautiously to the sequential decline in profitability, despite the positive news of becoming debt-free.
📈 Long termLong-term value creation depends on the successful deployment of the remaining ₹48.97 cr capex for new centers to drive volume growth.
⚠ Risk flags
- Slow execution of IPO-funded expansion
- Significant sequential margin compression
- High 'Other Expenses' relative to revenue
Key Highlights
Revenue from operations stood at ₹13.67 cr for the quarter ended June 30, 2026.
Net profit decreased to ₹1.66 cr from ₹7.73 cr in the preceding quarter (March 2026).
Completed repayment of ₹18.07 cr in borrowings using IPO proceeds, achieving zero-debt status.
Only ₹1.03 cr utilized out of ₹50.00 cr earmarked for new IVF center establishment.
Total IPO fresh issue proceeds of ₹90.00 cr saw a cumulative utilization of ₹34.03 cr by June 30, 2026.
👀 What to Watch
Investors should monitor the pace of capital expenditure for new IVF centers, as the company has deployed only 2% of the allocated ₹50 cr. The transition to a debt-free balance sheet is a positive structural change to watch in upcoming interest cost savings.
19-Centre Expansion: Gaudium IVF Launches AI-Powered Signature Lab in South Delhi
Gaudium IVF has launched its first milestone centre in South Delhi, marking the start of a planned 19-centre expansion outlined in its IPO roadmap. The new facility introduces the 'Signature Lab' model, which integrates AI-powered technologies like SiD and ERICA for advanced sperm and embryo assessment. With a reported Dec 2025 quarterly revenue of ₹24.51 cr, this 19-centre rollout represents a significant scaling effort relative to its current operations. The company aims to replicate this standardized clinical model across all upcoming locations to ensure consistent success rates.
Confidence: HIGH
What changedThe company has officially transitioned from its IPO phase to the execution of its physical expansion strategy by opening a high-tech flagship centre.
Why it mattersThis expansion is critical for scaling the business; if the 19-centre rollout is successful, it could significantly multiply the company's current revenue base of ~₹100 cr (annualized).
Planned expansion: 19 centresDec 2025 Revenue (Q): ₹24.507 crDec 2025 PAT (Q): ₹3.6305 crOperating Margin (Dec 2025): 26.7%
📅 Short termThe announcement is likely to be viewed positively by the market as it demonstrates management's commitment to its IPO growth promises.
📈 Long termIf the company successfully replicates its 'Signature Lab' model across 19 centres, it could establish a dominant position in the fragmented Indian IVF market.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in managing a rapid 19-centre rollout
- High competition in the premium fertility segment
- Gestation period of new centres may temporarily impact margins
Key Highlights
Commenced a planned 19-centre expansion as per the growth roadmap shared during its IPO
Introduced AI-powered embryology ecosystem including SiD (Sperm Identification Device) and ERICA (Embryo Ranking Assistant)
Company reported a net profit of ₹3.63 cr on revenue of ₹24.51 cr for the Dec 2025 quarter
The expansion leverages a 17-year legacy in fertility care and international quality benchmarks from ESQR, Spain
👀 What to Watch
Investors should monitor the execution timeline and capital expenditure for the remaining 18 centres and track the revenue ramp-up from the South Delhi facility in upcoming quarterly results.
Gaudium IVF to Start Operations at New South Extension Hub on July 16, 2026
Gaudium IVF and Women Health Limited has announced the commencement of commercial operations at its new IVF Centre/Hub in South Extension, New Delhi, effective July 16, 2026. This expansion is a direct execution of the objectives outlined in the company's IPO prospectus dated February 25, 2026. Given the company's Dec 2025 quarterly revenue of ₹24.51 cr, the addition of a new hub in a prime Delhi location represents a significant capacity increase. The facility is equipped with advanced embryology laboratories and modern medical infrastructure to provide specialized fertility services.
Confidence: HIGH
What changedThe company has transitioned its new South Extension facility from the development phase to active commercial operations.
Why it mattersThis expansion increases the company's service capacity and geographic reach in a high-demand urban market, supporting its post-IPO growth strategy.
Commencement Date: July 16, 2026Dec 2025 Quarterly Revenue: ₹24.507 crDec 2025 Quarterly PAT: ₹3.6305 crIPO Prospectus Date: February 25, 2026
📅 Short termThe announcement demonstrates timely execution of IPO promises, which is likely to be viewed positively by the market in the coming weeks.
📈 Long termThe addition of new hubs is critical for scaling the business in the fragmented IVF market; successful ramp-up here could lead to further regional expansions.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Gestation period for the new hub to reach break-point profitability
- High competition in the South Delhi healthcare market
Key Highlights
Commencement of commercial operations at the South Extension Part-II hub on July 16, 2026.
Expansion aligns with the IPO objects stated in the Prospectus dated February 25, 2026.
Company reported a quarterly revenue of ₹24.507 cr and PAT of ₹3.63 cr in Dec 2025.
The new facility features advanced embryology laboratories and a team of experienced fertility specialists.
👀 What to Watch
Monitor the upcoming quarterly results to assess the revenue contribution and margin impact of the new South Extension hub as it ramps up operations.
Gaudium IVF Approves ₹15 Crore Expansion for New Women Hospital in Lucknow
Gaudium IVF and Women Health Limited has approved the establishment of a new hospital in Lucknow, Uttar Pradesh, with an estimated project cost of ₹15 crore. The project will be developed through a 30-year long-term lease arrangement with a 15-year lock-in period. The company will pay 10% of net monthly revenue to the landowner, following the recovery of a ₹3 crore security deposit. This move signifies a strategic expansion into the North Indian healthcare market using an asset-light revenue-sharing model.
Key Highlights
Estimated project cost of up to ₹15 crore for construction, medical infrastructure, and equipment.
30-year lease agreement signed with a mandatory 15-year lock-in period for the Lucknow property.
Revenue-sharing model established at 10% of net revenue payable to the landowner.
Security deposit of ₹3 crore to be adjusted against future revenue share payments until fully recovered.
The facility will be a comprehensive women's hospital managed and operated entirely by Gaudium IVF.
👀 What to Watch
Investors should view this as a positive growth step that utilizes an asset-light model to expand geographical reach. Monitor the commissioning timeline and the subsequent impact on the company's operating margins.
Gaudium IVF FY26 Update: ARPP at Rs 2.98 Lakh, Plans Expansion to 11 Hubs by FY27
Gaudium IVF reported an Average Revenue Per Patient (ARPP) of Rs. 2,97,998 for FY26, supported by 2,255 OPU procedures. The company maintains a strong clinical success rate of 58% on the first attempt, which increases to 85% for multiple attempts. Revenue is primarily driven by IVF treatments (64%) and Pharmacy sales (31%). Management has outlined a clear expansion roadmap to add 3 new hubs in FY27 and 8 additional centers in FY28 to capitalize on the 13.1% CAGR projected for the Indian IVF market.
Key Highlights
Average Revenue Per Patient (ARPP) reached Rs. 2,97,998 with 2,255 OPU procedures completed.
Revenue mix is well-diversified with IVF treatments contributing 64% and Pharmacy contributing 31%.
Expansion strategy includes 3 new hubs in FY27 (Delhi/NCR and Nagpur) and 8 new centers in FY28.
AI-powered tools SiD and ERICA have contributed to an 8-9% increase in clinical success rates.
The company operates a network of 7 hubs and 28 spokes across 9 Indian states.
👀 What to Watch
Investors should track the timely execution of the FY27 hub launches as they are critical for scaling revenue. The company's focus on AI-driven clinical outcomes and high ARPP makes it a strong play in the consolidating organized IVF sector.
Gaudium IVF Q4 PAT up 29.5% to ₹8.36 Cr; FY26 Revenue crosses ₹100 Cr mark
Gaudium IVF reported a strong Q4FY26 with revenue growing 12.7% YoY to ₹30.35 Cr and PAT increasing 29.5% to ₹8.36 Cr. For the full year FY26, the company achieved a significant milestone with revenue jumping 47.6% to ₹104.35 Cr. EBITDA margins showed impressive expansion in Q4, reaching 40.1% compared to 32.4% in the previous year. The company is aggressively expanding its footprint, planning to increase its hub count from 7 to 10 in FY27 using IPO proceeds.
Key Highlights
Q4FY26 EBITDA grew 39.6% YoY to ₹12.17 Cr with margins expanding by 771 bps to 40.1%.
Full-year FY26 Revenue reached ₹104.35 Cr, a 47.6% increase over FY25's ₹70.72 Cr.
Maintained a high clinical pregnancy success rate of 58% on the first IVF attempt.
Announced integration of AI-led embryology platforms (SiD and ERICA) to improve outcomes.
Expansion plan on track to add 19 new hubs, with 3 expected to be operational shortly.
👀 What to Watch
Investors should monitor the execution of the hub expansion plan and the impact of AI integration on success rates. The strong margin profile and debt-light balance sheet make it a compelling growth play in the specialized healthcare segment.
Gaudium IVF FY26 Net Profit Rises 19.6% to ₹22.29 Cr; Q4 Revenue Jumps 32% YoY
Gaudium IVF and Women Health Limited reported a robust performance for the fiscal year ended March 31, 2026, with annual revenue from operations growing 21.3% to ₹7,157.85 Lakhs. Net profit for the full year increased to ₹2,228.77 Lakhs from ₹1,863.38 Lakhs in FY25, reflecting steady margin maintenance. The fourth quarter was particularly strong, with revenue hitting ₹2,216.60 Lakhs, a significant 56% increase over the preceding quarter. The company's equity base expanded significantly to ₹14,926.48 Lakhs, indicating a much stronger capital position compared to the previous year.
Key Highlights
Annual Revenue from operations grew 21.3% YoY to ₹7,157.85 Lakhs.
Net Profit for FY26 increased by 19.6% to ₹2,228.77 Lakhs compared to ₹1,863.38 Lakhs in FY25.
Q4 FY26 Net Profit stood at ₹773.14 Lakhs, up 24.5% compared to ₹620.92 Lakhs in Q4 FY25.
Total Equity surged to ₹14,926.48 Lakhs from ₹4,543.33 Lakhs, driven by a massive increase in 'Other Equity'.
Earnings Per Share (EPS) improved to ₹3.59 for the full year from ₹3.06 in the previous fiscal.
👀 What to Watch
Investors should maintain a positive outlook given the strong sequential growth in Q4 and healthy annual profit margins. The significant increase in the equity base suggests the company is well-positioned for future expansion or debt reduction.
NCLT Rejects Insolvency Petition Against Gaudium IVF Filed by Ramaa Capital
The Hon’ble National Company Law Tribunal (NCLT), New Delhi Bench, has dismissed an insolvency petition filed against Gaudium IVF and Women Health Limited. The petition, filed under Section 9 of the Insolvency and Bankruptcy Code (IBC) by Ramaa Capital, an operational creditor, was rejected via an order dated May 15, 2026. The company received the official copy of the order on May 22, 2026, and has confirmed that the dismissal has no adverse impact on its financial or operational activities. This resolution removes a significant legal overhang regarding the company's solvency status.
Key Highlights
NCLT New Delhi Bench rejected the Section 9 IBC petition (C.P. (IB)/243/ND/2026) filed by Ramaa Capital.
The order was passed on May 15, 2026, and officially received by the company on May 22, 2026.
Management confirms there is no impact on the company's financial, operational, or other activities.
The dismissal clears the company of potential Corporate Insolvency Resolution Process (CIRP) proceedings.
👀 What to Watch
Investors should view this as a positive development as it eliminates a potential legal threat to the company's operations. No further action is required, but shareholders should continue to monitor for any appeals by the creditor.
Gaudium IVF Launches India's First AI-Led Infertility Treatment via IVF 2.0 Collaboration
Gaudium IVF has introduced India's first AI-driven infertility treatment, integrating advanced embryology systems SiD and ERICA. This initiative, launched in collaboration with UK-based IVF 2.0, aims to improve fertilization and blastocyst development rates through precision sperm and embryo selection. As India's first publicly listed IVF chain, this move strengthens its competitive edge in the high-growth fertility market. The technology is expected to reduce repeat cycles, potentially lowering costs for patients while improving clinical outcomes and predictability.
Key Highlights
First Indian IVF chain to integrate AI-led embryology systems SiD and ERICA into routine clinical practice.
Strategic collaboration with UK-headquartered IVF 2.0 to bring globally advanced embryology intelligence to India.
SiD technology optimizes sperm selection while ERICA provides data-driven ranking of embryos to improve success rates.
The move comes just one month after the company became India's first publicly listed IVF chain.
Aims to reduce the need for repeat cycles, lowering the financial and emotional burden on patients.
👀 What to Watch
Investors should monitor the adoption rate of these AI services and their impact on the company's clinical success rates and margins. This technological leadership could differentiate Gaudium in a fragmented market and drive higher patient volumes.
Gaudium IVF Faces ₹29.21 Crore Arbitration Claim from Neomile Corporate Advisory
Gaudium IVF and Women Health Limited has been served with an arbitration petition by Neomile Corporate Advisory Limited in the Bombay High Court. The claimant is seeking interim measures for a payment of ₹29,20,50,000 (including GST) for alleged advisory services related to the company's IPO. Gaudium IVF has formally contested the claim, describing it as frivolous, unsubstantiated, and based on factual misstatements. The company is currently taking legal steps to safeguard its interests against this significant financial claim.
Key Highlights
Arbitration petition filed under Section 9 of the Arbitration & Conciliation Act, 1996.
Total claim amount involved is ₹29,20,50,000 inclusive of GST.
Dispute relates to alleged advisory services provided during the company's Initial Public Offering (IPO).
Matter is currently pending before the High Court of Judicature at Bombay.
Company management has officially labeled the petition as frivolous and contrary to evidence.
👀 What to Watch
Investors should monitor the progress of this litigation as an adverse ruling could result in a significant cash outflow of over ₹29 crore. While the company is defending the case, this represents a contingent liability that may impact short-term sentiment.
Gaudium IVF Reports Q3 FY26 Net Profit of ₹3.63 Cr; 9M FY26 Profit at ₹16.15 Cr
Gaudium IVF and Women Health Limited announced its first financial results post-listing, reporting a revenue of ₹24.51 crore and a net profit of ₹3.63 crore for Q3 FY26. For the nine-month period ended December 31, 2025, the company achieved a total income of ₹74.36 crore and a net profit of ₹16.15 crore. The company recently completed its IPO in February 2026, raising approximately ₹165 crore to fund its expansion in the high-growth fertility care market. These results reflect healthy margins and operational discipline as the company transitions into a listed entity.
Key Highlights
Q3 FY26 revenue from operations stood at ₹2,450.70 lakh with a net profit of ₹363.05 lakh.
9M FY26 total income reached ₹7,435.97 lakh with a robust profit before tax of ₹2,174.59 lakh.
Successfully listed on NSE and BSE on February 27, 2026, after raising ₹16,500.10 lakh via IPO.
Maintained healthy margins through operating leverage and disciplined cost management across its multi-city network.
👀 What to Watch
The company shows strong profitability in its debut results, making it a key player to watch in the specialized healthcare segment. Investors should track the utilization of IPO funds for network expansion and clinical infrastructure.
Gaudium IVF Q3 FY26 Standalone Revenue at ₹14.19 Cr; 9M Net Profit Grows 17% YoY
Gaudium IVF reported a standalone revenue of ₹14.19 crore for Q3 FY26, showing marginal growth over the ₹13.95 crore reported in Q3 FY25. Quarterly net profit dipped slightly to ₹3.18 crore from ₹3.35 crore YoY, primarily due to higher tax provisions. For the nine-month period ended December 2025, the company demonstrated stronger performance with a 17% increase in net profit to ₹14.56 crore. These results precede the company's successful IPO and listing on the exchanges in February 2026.
Key Highlights
Standalone Q3 FY26 revenue increased slightly to ₹1,419.35 Lakhs from ₹1,394.66 Lakhs YoY.
Net profit for Q3 FY26 saw a marginal decline to ₹318.40 Lakhs compared to ₹334.52 Lakhs in the previous year.
Nine-month (9M FY26) revenue grew to ₹4,941.25 Lakhs, up from ₹4,217.87 Lakhs in 9M FY25.
The company successfully listed on NSE and BSE on February 27, 2026, at an issue price of ₹79 per share.
Total comprehensive income for the nine-month period reached ₹1,461.43 Lakhs.
👀 What to Watch
The company is in its early stages as a listed entity; investors should watch for margin improvements and the utilization of IPO proceeds for expansion. The 9M growth trend is positive, though quarterly volatility in profits warrants a cautious approach.
